{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-001469","form_type":"8-K","ticker":"WINT","cik":"0000946486","company_name":"WINDTREE THERAPEUTICS INC /DE/","filed_at":"2024-01-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.384804+00:00","generated_at":"2026-06-06T22:54:43.082440+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Windtree licenses cardio drugs to Lee's for up to $138M milestones; PM deals restructured","bullets":["Lee's gets exclusive rights to istaroxime, rostafuroxin, SERCA2a activators in 14 Asian countries for heart failure and cardiogenic shock.","Windtree eligible for up to $3.1M in pre-development/regulatory milestones and $135.25M in sales milestones, plus low double-digit sublicense income.","Tiered royalties from low single-digit to low double-digit on net sales, subject to reduction by up to 50% under generic competition.","PM USA/PMPSA amendments: Windtree pays $500k fixed plus $1.4M milestones, extinguishes quarterly payments."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-001469","json":"https://secwatch.observer/filing/0001437749-24-001469.json","markdown":"https://secwatch.observer/filing/0001437749-24-001469.md","text":"https://secwatch.observer/filing/0001437749-24-001469.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946486/000143774924001469/0001437749-24-001469-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946486/000143774924001469/wint20240116_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T22:54:43.082440+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"800aa4a44211f60401cda5ec7d3ef68a93ce5e2f","claim":"WINDTREE THERAPEUTICS INC /DE/ entered into License, Development and Commercialization Agreement with Lee's Pharmaceutical (HK) Ltd. with Lee's Pharmaceutical (HK) Ltd. valued at up to $3.1 million in potential upfront pre-development, development, clinical, and regulatory miles (effective 2023-01-07).","evidence_excerpt":"On January 12, 2024 Windtree Therapeutics, Inc. (the “ Company ”) entered into a License, Development and Commercialization Agreement with Lee’s Pharmaceutical (HK) Ltd., a company organized under the laws of Hong Kong (“ Lee ’ s ”), effective as of January 7, 2023 (the “ Lee ’ s License Agreement ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/946486/000143774924001469/0001437749-24-001469-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Lee's Pharmaceutical (HK) Ltd."},{"label":"Value","value":"up to $3.1 million in potential upfront pre-development, development, clinical, and regulatory miles"},{"label":"Effective","value":"2023-01-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}